MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX

MYX - MAYNE PHARMA GROUP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 1.45
Index: ALL-ORDS

Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.50

29 Oct
2026

-0.130

OPEN

$2.65

-4.94%

HIGH

$2.65

418,627

LOW

$2.46

TARGET
$4.20 68.0% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MYX: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 30.6 15.5 xxx
DPS (cps) xxx 0.0 N/A xxx
EPS Growth xxx N/A - 49.4% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 16.4 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx30.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx383.7 M
Book Value Per Share xxxxxxxxxxxxxxx481.2
Net Operating Cash Flow xxxxxxxxxxxxxxx15.6 M
Net Profit Margin xxxxxxxxxxxxxxx8.13 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx8.20 %
Return on Invested Capital xxxxxxxxxxxxxxx8.15 %
Return on Assets xxxxxxxxxxxxxxx3.24 %
Return on Equity xxxxxxxxxxxxxxx8.20 %
Return on Total Capital xxxxxxxxxxxxxxx-8.02 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx12.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx42 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx43 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx82 M
Price To Book Value xxxxxxxxxxxxxxx0.58

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx3.3 M
Capex % of Sales xxxxxxxxxxxxxxx0.87 %
Cost of Goods Sold xxxxxxxxxxxxxxx191 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx226 M
Research & Development xxxxxxxxxxxxxxx21 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

27/10/2026

1

Initiation of coverage with Speculative Buy

$4.20

68.00%

Ord Minnett initiates coverage of Mayne Pharma with a Speculative Buy rating and $4.20 target, seeing an opportunity after the share price fell more than -60% following the failed Cosette takeover.

The broker highlights accelerating Women's Health revenue, supported by menopause treatment demand and the removal of boxed safety warnings for Bijuva, Mayne's oral hormone replacement therapy (HRT).

Commentary adds growth in direct-to-patient platform DistributeRx is helping offset Dermatology headwinds, while undervalued assets offer strategic opportunities.

Key risks are thought to include reimbursement changes, generic competition and execution.

FORECAST
Ord Minnett forecasts a full year FY27 EPS of 15.50 cents.
Ord Minnett forecasts a full year FY28 EPS of 20.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

30/08/2026

1

Speculative Buy

$3.75

50.00%

Canaccord Genuity retains a Speculative Buy rating for Mayne Pharma with its target price decreased to $3.75 from $3.83 following a transitional FY26 defined by Cosette-related disruption.

The broker notes underlying EBITDA of $34.2m and closing cash of $80.0m slightly exceeded expectations.

The analyst lowers the target price and FY27 cash projections due to continued erosion and lower pricing within the Dermatology segment.

The investment thesis hinges on executing balance sheet simplification within 12 months, specifically selling the International Business and Salisbury facility for an estimated $70m to repay convertible notes and buy out licensing arrangements.

Canaccord anticipates increased investment will drive top-line growth in the strategically appealing Women's Health portfolio.
Access Extra Coverage Research History >

MYX STOCK CHART

FNArena News on MYX

1
Australian Broker Call *Extra* Edition – Aug 31, 2026

Aug 31 2026 - Daily Market Reports
2
Next Week At A Glance – 10-14 Aug 2026

Aug 07 2026 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Aug 04, 2026

Aug 04 2026 - Daily Market Reports
4
Next Week At A Glance – 20-25 Jul 2026

Jul 17 2026 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Jul 06, 2026

Jul 06 2026 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Telix Aims For A Strategic Isotope Supply Chain

Sep 24 2026 - Australia
2
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
3
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
4
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
5
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
6
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
7
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
8
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
9
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
10
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals